DOP2012000091A - Combinaciones utiles para el tratamiento de cancer en un mamifero - Google Patents

Combinaciones utiles para el tratamiento de cancer en un mamifero

Info

Publication number
DOP2012000091A
DOP2012000091A DO2012000091A DO2012000091A DOP2012000091A DO P2012000091 A DOP2012000091 A DO P2012000091A DO 2012000091 A DO2012000091 A DO 2012000091A DO 2012000091 A DO2012000091 A DO 2012000091A DO P2012000091 A DOP2012000091 A DO P2012000091A
Authority
DO
Dominican Republic
Prior art keywords
phenyl
mammer
cancer treatment
useful combinations
raf
Prior art date
Application number
DO2012000091A
Other languages
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of DOP2012000091A publication Critical patent/DOP2012000091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una combinación novedosa que comprende el inhibidor de MEK de N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenil-amino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido-[4,3-d]-pirimidin-1-il]-fenil}-acetamida, o una sal farmacéuticamente aceptable o un solvato de la misma, con un inhibidor de B-Raf, en particular N-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetil-etil)-1,3-tiazol-4-il]-2-fluoro-fenil}-2,6-difluoro-bencen-sulfonamida o una sal farmacéuticamente aceptable de la misma, composiciones farmacéuticas que la comprenden, y métodos para utilizar estas combinaciones y composiciones en el tratamiento de las condiciones en donde sea benéfica la inhibición de MEK y/o B-Raf, por ejemplo, cáncer.
DO2012000091A 2009-10-16 2012-04-03 Combinaciones utiles para el tratamiento de cancer en un mamifero DOP2012000091A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
DOP2012000091A true DOP2012000091A (es) 2013-09-15

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000091A DOP2012000091A (es) 2009-10-16 2012-04-03 Combinaciones utiles para el tratamiento de cancer en un mamifero

Country Status (34)

Country Link
US (3) US8703781B2 (es)
EP (4) EP4397376A2 (es)
JP (1) JP5718929B2 (es)
KR (1) KR101729116B1 (es)
CN (1) CN102655753B (es)
AU (1) AU2010306653B2 (es)
BR (1) BR112012008854B8 (es)
CA (1) CA2775803C (es)
CL (1) CL2012000964A1 (es)
CO (1) CO6531498A2 (es)
CR (1) CR20120155A (es)
CY (1) CY1122013T1 (es)
DK (3) DK3560498T3 (es)
DO (1) DOP2012000091A (es)
EA (1) EA020589B1 (es)
ES (2) ES2745479T3 (es)
FI (1) FI4159217T3 (es)
HR (2) HRP20221304T1 (es)
HU (2) HUE060206T2 (es)
IL (1) IL219073A (es)
LT (2) LT3560498T (es)
MA (1) MA33746B1 (es)
ME (1) ME03497B (es)
MX (1) MX2012004413A (es)
MY (1) MY174759A (es)
NZ (1) NZ598913A (es)
PE (1) PE20121093A1 (es)
PL (2) PL2488033T3 (es)
PT (2) PT2488033T (es)
RS (2) RS63702B1 (es)
SI (1) SI2488033T1 (es)
UA (1) UA105064C2 (es)
WO (1) WO2011047238A1 (es)
ZA (1) ZA201202612B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
CA2962524C (en) 2008-06-16 2020-07-14 University Of Tennessee Research Foundation (2-(1-h-indolyl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone useful for the treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013096430A1 (en) * 2011-12-22 2013-06-27 Glaxosmithkline Llc Method of treating cancer with magea3 immunotherapeutic with braf inhibitor and/or mek inhibitor
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
DK2892535T3 (da) * 2012-09-04 2022-01-03 Novartis Ag Fremgangsmåde til adjuverende cancerbehandling
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
PL2925299T3 (pl) * 2012-11-30 2018-11-30 Novartis Ag Nowa kompozycja farmaceutyczna
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
KR102246652B1 (ko) 2013-03-05 2021-04-29 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
MA38643A1 (fr) * 2013-06-03 2017-10-31 Novartis Ag Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
EP3079698A1 (en) * 2013-12-12 2016-10-19 Novartis AG Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CA3042697A1 (en) * 2016-11-03 2018-05-11 The Regents Of The University Of Michigan Small molecule dual inhibitors of egfr/pi3k and uses thereof
CN112867803A (zh) 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN112294965B (zh) * 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANCER IN DOGS
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
AU2022381730A1 (en) * 2021-11-02 2024-05-02 Verastem, Inc. Methods of treating abnormal cell growth
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
NZ518032A (en) * 1999-11-22 2004-02-27 Smithkline Beecham Plc Substituted imidazole derivatives
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP2175885B1 (en) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
EA020589B1 (ru) 2014-12-30
IL219073A (en) 2016-05-31
DK2488033T3 (da) 2019-09-02
FI4159217T3 (fi) 2024-08-15
UA105064C2 (uk) 2014-04-10
LT3560498T (lt) 2022-11-25
MA33746B1 (fr) 2012-11-01
PL2488033T3 (pl) 2019-12-31
AU2010306653A1 (en) 2012-05-10
EP3560498A1 (en) 2019-10-30
EA201290149A1 (ru) 2012-11-30
CO6531498A2 (es) 2012-09-28
CL2012000964A1 (es) 2012-08-31
RS59181B1 (sr) 2019-10-31
CN102655753B (zh) 2015-11-25
ES2745479T3 (es) 2020-03-02
ZA201202612B (en) 2013-09-25
AU2010306653B2 (en) 2013-10-24
SI2488033T1 (sl) 2019-10-30
ME03497B (me) 2020-04-20
HUE046139T2 (hu) 2020-02-28
HUE060206T2 (hu) 2023-02-28
EP2488033A1 (en) 2012-08-22
CN102655753A (zh) 2012-09-05
BR112012008854B1 (pt) 2020-12-29
US20140187566A1 (en) 2014-07-03
HRP20221304T1 (hr) 2022-12-23
KR101729116B1 (ko) 2017-05-02
BR112012008854B8 (pt) 2021-05-25
CA2775803C (en) 2017-11-21
MY174759A (en) 2020-05-13
PT2488033T (pt) 2019-09-10
IL219073A0 (en) 2012-06-28
US8703781B2 (en) 2014-04-22
DK3560498T3 (da) 2022-11-14
DK4159217T3 (da) 2024-08-12
MX2012004413A (es) 2012-05-08
BR112012008854A2 (pt) 2015-09-22
EP2488033B1 (en) 2019-06-12
CA2775803A1 (en) 2011-04-21
CR20120155A (es) 2012-07-05
PT3560498T (pt) 2022-11-03
KR20120104547A (ko) 2012-09-21
US8952018B2 (en) 2015-02-10
NZ598913A (en) 2013-11-29
RS63702B1 (sr) 2022-11-30
LT2488033T (lt) 2019-09-10
JP5718929B2 (ja) 2015-05-13
EP4397376A2 (en) 2024-07-10
EP2488033A4 (en) 2014-04-30
PL3560498T3 (pl) 2022-12-12
PE20121093A1 (es) 2012-09-04
CY1122013T1 (el) 2020-10-14
WO2011047238A1 (en) 2011-04-21
HRP20191617T1 (hr) 2019-12-13
ES2930157T3 (es) 2022-12-07
JP2013508294A (ja) 2013-03-07
EP4159217A1 (en) 2023-04-05
EP3560498B1 (en) 2022-08-17
US20120196879A1 (en) 2012-08-02
EP4159217B1 (en) 2024-05-22
US20150111904A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
DOP2012000091A (es) Combinaciones utiles para el tratamiento de cancer en un mamifero
PH12015502415A1 (en) Combinations
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CR9901A (es) Combinaciones antineoplasicas con inhibidor de objetivo de rapamicina en mamiferos, herceptina, y/o hki-272
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
ECSP11011136A (es) Compuestos útiles para inhibir chk1
BR112016011222A2 (pt) Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2012000755A1 (es) Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
AR054253A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
BR112015009134A2 (pt) combinação
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
BR112012011677A2 (pt) combinação, kit de combinação e uso de uma combinação
AR065077A1 (es) Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos
CL2009000264A1 (es) Uso de una combinacion farmaceutica que comprende una sal de bis-tiazolio o uno de sus precursores y artemisina o uno de sus derivados, para el tratamiento y/o prevencion de la malaria severa; uso de la composicion farmaceutica y del kit farmaceutico que la comprenden.
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
CL2008002555A1 (es) Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia.